Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation

•Comparisons of smoking cessation trials demonstrate inconsistent genetic results.•A placebo control arm is important to determine the pharmacogenetic effect.•Individuals with risk genotypes have difficulty quitting smoking without treatment.•This increased risk may be ameliorated by effective pharmacological treatment.